Scientists claim to have found a way to restore vision in people with a common developmental eye disorder by “rebooting” the retina to its early state, enabling it to grow and cure itself.Researchers ...

Strategy Inc. (NASDAQ:MSTR) is one of the best cryptocurrency stocks to buy for the long term. On November 11, TD Cowen ...

Once upon a time, dry eye disease was simple.Like a desert, an eye with dry eye disease (DED) simply had too little water to ...

EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of high-dose Eylea despite outstanding manufacturing concerns.

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

Temporarily anesthetizing the retina briefly reverts the activity of the visual system to that observed in early development ...

What if instead of temporarily relieving your allergies with medication, you could train your immune system to stop overreacting to your allergens altogether? That's the idea behind ...

A growing number of 20-somethings are trying to freeze time with preventative Botox treatments. Here's what's behind the ...

Podcaster Bobbi Althoff detailed her experience with getting Botox to help treat her chronic jaw pain, sharing her “face is ...